Question

The study randomly assigned 13,608 patients with moderate-to-high-risk of acute coronary syndromes with percutaneous coronary intervention to receive either: Prasugrel (a 60 mg loading dose and a 10 mg daily maintenance dose), for 6 to 15 months. Clopidogrel (a 300 mg loading dose and a 75 mg maintenance dose), for 6 to 15 months. The primary efficacy endpoint was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety endpoint was major bleeding Which of the following is the control? Select one: O O a. Clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) b. Death from cardiovascular causes c. Nonfatal myocardial infarction d. Major bleeding O e. Prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose)

Answer 1

ANSWER

e. Prasugrel ( a 60 mg loading dose and a 10 mg daily maintenance dose) is

    the control.

   * Prasugrel is more effective than clopidogrel against cardiovascular diseases

     but risk of prasugrel therapy is major bleeding so it can consider as control.